XML 96 R87.htm IDEA: XBRL DOCUMENT
v3.22.1

Litigation (Drug Pricing Matters) (Details) - Mar. 31, 2022 | Total | state
--- | --- | ---
Multi District Litigation [Member] |  |
Loss Contingencies [Line Items] |  |
Number of states | 46 | 46
Anticompetitive Conduct with Doxycycline Hyclate Delayed Release, Doxycycline Monohydrate, Glipizide-Metformin and Verapamil [Member] |  |
Loss Contingencies [Line Items] |  |
Number of states | 36 |
Anticompetitive Conduct with Generic Drugs [Member] |  |
Loss Contingencies [Line Items] |  |
Number of states | 47 |
Amended Anticompetitive Conduct with Generic Drugs [Member] |  |
Loss Contingencies [Line Items] |  |
Number of states | 42 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of states + References No definition available. + Details
Name: | vtrs_Numberofstates
Namespace Prefix: | vtrs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_MultiDistrictLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithDoxycyclineHyclateDelayedReleaseDoxycyclineMonohydrateGlipizideMetforminandVerapamilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AnticompetitiveConductwithGenericDrugsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=vtrs_AmendedAnticompetitiveConductwithGenericDrugsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |